These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 19021299

  • 1. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient.
    Johnson RW, Wasner G, Saddier P, Baron R.
    Drugs Aging; 2008; 25(12):991-1006. PubMed ID: 19021299
    [Abstract] [Full Text] [Related]

  • 2. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.
    Johnson RW.
    Aging Clin Exp Res; 2009 Jun; 21(3):236-43. PubMed ID: 19571648
    [Abstract] [Full Text] [Related]

  • 3. Herpes zoster and postherpetic neuralgia.
    Johnson RW.
    Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):21-6. PubMed ID: 20192714
    [Abstract] [Full Text] [Related]

  • 4. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study.
    Schmidt-Ott R, Schutter U, Simon J, Nautrup BP, von Krempelhuber A, Gopala K, Anastassopoulou A, Guignard A, Curran D, Matthews S, Espié E.
    J Infect; 2018 May; 76(5):475-482. PubMed ID: 29428228
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM, Brisson M, Levin MJ.
    Vaccine; 2007 Nov 28; 25(49):8326-37. PubMed ID: 17980938
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan.
    Yaegashi M, Matsui H, Yoshida A, Ban H, Miyazaki R, Oda N, Hattori K, Motomura Y, Usami H, Matsushita H.
    Vaccine; 2024 Jan 25; 42(3):464-470. PubMed ID: 38172019
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prevention of herpes zoster and its painful and debilitating complications.
    Johnson R, McElhaney J, Pedalino B, Levin M.
    Int J Infect Dis; 2007 Nov 25; 11 Suppl 2():S43-8. PubMed ID: 18162246
    [Abstract] [Full Text] [Related]

  • 10. Herpes zoster vaccine: A health economic evaluation for Switzerland.
    Blank PR, Ademi Z, Lu X, Szucs TD, Schwenkglenks M.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1495-1504. PubMed ID: 28481678
    [Abstract] [Full Text] [Related]

  • 11. [Herpes Zoster and its prevention in Italy. Scientific consensus statement].
    Franco E, Gabutti G, Bonanni P, Conversano M, Stefano Valente ME, Ferro A, Icardi G, Antonio Volpi ML, Maggi S, Rossi A, Scotti S, Vitale F, Greco D, Italian Universities and Epidemiology.
    Ig Sanita Pubbl; 2014 Jul 03; 70(1):111-27. PubMed ID: 24770367
    [Abstract] [Full Text] [Related]

  • 12. Vaccination: a new option to reduce the burden of herpes zoster.
    Mick G.
    Expert Rev Vaccines; 2010 Mar 03; 9(3 Suppl):31-5. PubMed ID: 20192716
    [Abstract] [Full Text] [Related]

  • 13. Herpes zoster and postherpetic neuralgia in Catalonia (Spain).
    Salleras L, Salleras M, Salvador P, Soldevila N, Prat A, Garrido P, Domínguez A.
    Hum Vaccin Immunother; 2015 Mar 03; 11(1):178-84. PubMed ID: 25483532
    [Abstract] [Full Text] [Related]

  • 14. Increasing incidence associated with herpes zoster infection in British Columbia, Canada.
    Marra F, Chong M, Najafzadeh M.
    BMC Infect Dis; 2016 Oct 20; 16(1):589. PubMed ID: 27765026
    [Abstract] [Full Text] [Related]

  • 15. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
    Tseng HF, Lewin B, Hales CM, Sy LS, Harpaz R, Bialek S, Luo Y, Jacobsen SJ, Reddy K, Huang PY, Zhang J, Anand S, Bauer EM, Chang J, Tartof SY.
    J Infect Dis; 2015 Oct 15; 212(8):1222-31. PubMed ID: 26038400
    [Abstract] [Full Text] [Related]

  • 16. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine.
    Schmader K, Gnann JW, Watson CP.
    J Infect Dis; 2008 Mar 01; 197 Suppl 2():S207-15. PubMed ID: 18419399
    [Abstract] [Full Text] [Related]

  • 17. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
    Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O.
    BMC Health Serv Res; 2013 Sep 26; 13():359. PubMed ID: 24070414
    [Abstract] [Full Text] [Related]

  • 18. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
    Brisson M, Pellissier JM, Camden S, Quach C, De Wals P.
    Hum Vaccin; 2008 Sep 26; 4(3):238-45. PubMed ID: 18382137
    [Abstract] [Full Text] [Related]

  • 19. Vaccination against herpes zoster in developed countries: state of the evidence.
    Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M.
    Hum Vaccin Immunother; 2013 May 26; 9(5):1177-84. PubMed ID: 23324598
    [Abstract] [Full Text] [Related]

  • 20. A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia.
    Holcomb K, Weinberg JM.
    J Drugs Dermatol; 2006 Oct 26; 5(9):863-6. PubMed ID: 17039651
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.